Most Read Articles
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).

Studies show benefits of skin cancer screening, but with very low evidence

25 Jan 2017

Skin cancer screening appears to offer benefits based on large ecological studies, a cohort study, a case-control study and a survey, but the evidence level of these reports is very low.

Investigators searched Medline and Embase for research papers published in English or German between 1 January 2005 and 4 February 2015 to update evidence on the impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence, mortality, stage-specific incidence and interval cancers after negative screening.

Study selection, data extraction and critical appraisal were done by two independent reviewers. The results were described in a narrative synthesis. The systematic review included 15 articles from the 2,066 records identified in databases and 10 records found by manual search.

The incidence of in situ and invasive skin cancer rose with the implementation of skin cancer screening based on evidence gathered. Also, researchers found increasing rates of thin and decreasing rates of thick melanoma.

The incidence of invasive melanoma decreased after cessation of screening.

A German study showed a significant decrease in melanoma mortality, while two other reports observed fewer deaths than expected. There was no study on interval cancers identified.

The systematic review had certain weaknesses, including publication bias and the inherent limitation of the studies included due to their ecological design, according to researchers.

Wernli and colleagues presented in a report that, on a population level, no clear statement could be made regarding the benefit of skin cancer screening for melanoma mortality and all-cause mortality or association with thinner lesions due to limited evidence. [Wernli KJ, et al, AHRQ 2016 Report No. 14-05210-EF-1]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).